Fig. 1From: Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacistFigure shows the survey proposed by Clinician every month during treatment period. According to possible changes in health status perceived by the patient as well as any relevant clinical and laboratory condition, adverse events notification were reported and discussed with Hospital Pharmacist and entered in the online based Italian system for adverse drug reaction notificationsBack to article page